Sigma Advanced Systems Limited

NSE: SIGMAADVBSE: 532408
Compare with peers
₹ 904.30▲ 43 (+4.99%)28 Oct, 03:28 pm IST
P/E
89.3x
52-week range
140.1 – 1,165
ROE
91%
ROCE
61%
Sector
Aerospace & Defense
Industry
Aerospace & Defense
Listed on
NSE, BSE

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Aerospace & Defense: 33 companies →

Sigma Advanced Systems Limited against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)89.3 against a typical 72.2: pricier than most peers (1st = cheapest).21st of 33
  • Sales growth+7,380% against a typical +30.4% from a year earlier.1st of 28
  • Profit growth−74.3% against a typical +8.9% from a year earlier.21st of 27
  • Share price, 3 months+42.3% against a typical −2%.5th of 32

Latest announcements

Exchange filings and their impact on the company.

  • 26 Oct 2026Press ReleaseHigh impactVery positivePrice +5% on 27 Oct
    Sigma wins Rs 973 cr 12-month NATO order for base bleed units, more than doubling its TTM revenue run-rate.

    Sigma Advanced Systems has secured a USD 102.23 million (about Rs 973 crore) order from a NATO customer for Base Bleed Units used in 155mm artillery ammunition. The order is to be manufactured and supplied over 12 months and builds on its existing shells and fuzes capabilities. It significantly scales the company's defence ammunition business and advances its vertical integration strategy.

    Filing
  • 21 Oct 2026Press ReleaseHigh impactPositivePrice −5% that day
    Sigma won a Rs174 crore NATO 155mm subsystems order for delivery by Q2 2027, adding ~20% of TTM sales.

    Sigma Advanced Systems secured a US$19.7 million (approx Rs174 crore) order from a North American NATO customer for specialised ancillary subsystems for 155mm artillery ammunition, to be manufactured in its ecosystem and executed by Q2 2027. It is Sigma's fifth 155mm engagement since May 2026, after filled fuzes, M107 and base-bleed shell bodies and a course-correction fuze MoU, broadening it beyond shell bodies and fuzes. The order adds about 20% of TTM sales and supports its move toward integrated ammunition manufacturing for global rearmament demand.

    Filing
  • 14 Oct 2026Press ReleaseLow impactPositivePrice −2.4% that day
    Sigma signed an exclusive MoU with Munitions India to localise 155mm course-correction fuze technology.

    Sigma Advanced Systems has signed an exclusive MoU with Munitions India Limited to bring its 155mm artillery course-correction fuze technology to India. The plan covers technology transfer, qualification, local manufacturing and integration of the guidance kits for precision artillery ammunition. It is an early-stage collaboration with no order value disclosed, so near-term financial impact is small but it positions Sigma higher up the defence value chain in line with Make in India.

    Filing

Board meetings

Results dates and other board meetings. Full calendar

Details
13 Aug 2026Financial ResultsTo consider and approve the financial results for the quarter ended Jun 30, 2026 - Prior Intimation of Board Meeting pursuant to Regulation 29 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
4 Jun 2026Fund RaisingTo consider Fund Raising-Intimation under Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ( SEBI Listing Regulations )
25 May 2026Financial ResultsTo consider and approve the financial results for the period ended March 31, 2026- Prior Intimation of Board Meeting pursuant to Regulation 29 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
14 Feb 2026Financial ResultsTo consider and approve the financial results for the period ended December 31, 2025-Prior Intimation of Board Meeting pursuant to Regulation 29 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
8 Nov 2025Financial ResultsTo consider and approve the financial results for the period ended September 30, 2025-Prior Intimation of Board Meeting pursuant to Regulation 29 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
8 Aug 2025Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2025-Prior Intimation of Board Meeting pursuant to Regulation 29 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Share price

1Y change +378.59%
0 of 3 filing days came with a big price move
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales000001957518146323374
Expenses2212219402017139268313
Operating Profit−2−2−1−2−2016−15175561
OPM %—————−2.2%29%−291%6%4.6%17%16%
Other Income118889131318845893
Interest4454455405118
Depreciation111111111678
Profit before tax400116231683012749
Tax %2%0%0%0%0%22%22%18%0%550%1%22%
Net Profit−3−5−8−17−14791364−112835
EPS in Rs−0.44−0.65−1.1−2.27−1.930.991.1718.490.57−0.147.291.36

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
23%
5 Years
53%
3 Years
530%
TTM
964%
Compounded Profit Growth
10 Years
71%
5 Years
172%
3 Years
228%
TTM
20%
Stock Price CAGR
10 Years
48%
5 Years
123%
3 Years
141%
TTM
—
Return on Equity
10 Years
14%
5 Years
24%
3 Years
36%
TTM
—

Shareholding

Latest: Jul 2026.

Promoters
66.24%
+31.17 pts in a year
FIIs
0.13%
−0.38 pts in a year
DIIs
0.02%
+0.02 pts in a year
Public
33.61%
−30.81 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 89.3xEPS (12 months) ₹ 10.36Median P/E 20.9x
P/E (times)EPS (₹)

Prices are delayed and for information only. Nothing on this page is investment advice.